Details
Stereochemistry | ACHIRAL |
Molecular Formula | C2H4O3 |
Molecular Weight | 76.0514 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCC(O)=O
InChI
InChIKey=AEMRFAOFKBGASW-UHFFFAOYSA-N
InChI=1S/C2H4O3/c3-1-2(4)5/h3H,1H2,(H,4,5)
Molecular Formula | C2H4O3 |
Molecular Weight | 76.0514 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
SODIUM GLYCOLATE, a sodium salt of carboxymethyl ether, is used as a pharmaceutical grade dissolution excipient for solid dosage forms. It absorbs water rapidly, resulting in swelling which leads to the rapid disintegration of tablets and capsules. Without a disintegrant, these may not dissolve appropriately and may effect the amount of active ingredient absorbed, thereby decreasing effectiveness.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | CLEAR CELL SALICYLIC CLARIFYING TONIC Approved UsePrevention and treatment of Acne and acne-prone skin. A salicylic/glycolic acid skin clarifying removes excess surface oil. A blend of anti-oxidants leaves skin fresh and shine-free. Launch Date1.26230397E12 |
PubMed
Title | Date | PubMed |
---|---|---|
Simultaneous determination of ethylene glycol and glycolic acid in serum by gas chromatography-mass spectrometry. | 1999 Nov-Dec |
|
Intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical cancer. | 2001 |
|
The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer. | 2001 |
|
Molecular biology of the plastidic phosphorylated serine biosynthetic pathway in Arabidopsis thaliana. | 2001 |
|
Cytocidal effect and DNA damage of nedaplatin in vitro by simulating pharmacokinetic parameters. | 2001 Apr |
|
The gene yghK linked to the glc operon of Escherichia coli encodes a permease for glycolate that is structurally and functionally similar to L-lactate permease. | 2001 Apr |
|
Combinatory anti-tumor effects of electroporation-mediated chemotherapy and wild-type p53 gene transfer to human esophageal cancer cells. | 2001 Apr |
|
Iron coordination in photosystem II: interaction between bicarbonate and the QB pocket studied by Fourier transform infrared spectroscopy. | 2001 Apr 3 |
|
Activity staining of isocitrate lyase after electrophoresis on either native or sodium dodecyl sulfate polyacrylamide gels. | 2001 Aug |
|
Ethylene glycol-mediated tubular injury: identification of critical metabolites and injury pathways. | 2001 Aug |
|
An easy screening method for fungi producing ochratoxin A in pure culture. | 2001 Dec 30 |
|
Bioadhesive properties of hydroxypropylcellulose topical films produced by hot-melt extrusion. | 2001 Feb 23 |
|
Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer. | 2001 Jan |
|
Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. | 2001 Jan |
|
Phase I/II study of intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical carcinoma. | 2001 Jan 1 |
|
[Concurrent chemoradiation therapy with nedaplatin for high-risk cervical cancer--clinical investigation of adverse events]. | 2001 Jul |
|
[Targetting intra-arterial infusion chemotherapy with nedaplatin for oral cancer]. | 2001 Jul |
|
[A case of esophageal carcinoma with multiple liver metastases successfully treated with nedaplatin (NDP) and 5-fluorouracil (5-FU) combined with radiotherapy]. | 2001 Jun |
|
Reversal of cisplatin resistance by the 1,4-benzothiazepine derivative, JTV-519. | 2001 Jun |
|
[Concurrent chemoradiotherapy for advanced cervical cancer--a pilot study]. | 2001 Mar |
|
Local structure analysis of Ti species stabilized in ion exchangeable layer solids by x-ray absorption spectroscopy. | 2001 Mar 1 |
|
Surface modification of polyhydroxyalkanoate films and their interaction with human fibroblasts. | 2001 Mar 14 |
|
Plant tissue-based chemiluminescence flow biosensor for glycolic acid. | 2001 Mar 15 |
|
[Small cell carcinoma of the urinary bladder: a case report]. | 2001 Oct |
|
Sequence-dependent antitumor efficacy of combination chemotherapy with nedaplatin, a newly developed platinum, and paclitaxel. | 2001 Oct 22 |
|
Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. | 2001 Sep |
|
Influence of adjuvants on the dissolution profile of tablets containing high doses of spray-dried extract of Maytenus ilicifolia. | 2001 Sep |
|
Identification of a set of genes involved in the formation of the substrate for the incorporation of the unusual "glycolate" chain extension unit in ansamitocin biosynthesis. | 2002 Apr 24 |
|
Potential mechanisms of marked hyperoxaluria not due to primary hyperoxaluria I or II. | 2002 Aug |
|
Phase I study of combination chemotherapy with 5-fluorouracil (5-FU) and nedaplatin (NDP): adverse effects and eecommended dose of NDP administered after 5-FU. | 2002 Dec |
|
[Current and future state of chemoradiotherapy for head and neck cancer]. | 2002 Feb |
|
Transport of L-Lactate, D-Lactate, and glycolate by the LldP and GlcA membrane carriers of Escherichia coli. | 2002 Jan 18 |
|
Epithelial ovarian cancer: second and third line chemotherapy (review). | 2002 Jul |
|
Chemical characterisation of sodium starch glycolate particles. | 2002 Jun 20 |
|
An inherited metabolic disorder presenting as ethylene glycol intoxication in a young adult. | 2002 Mar |
|
[Combination chemotherapy with nedaplatin (CDGP) and 5-FU for oral cancer]. | 2002 Mar |
|
Synthesis of a novel class of polyhydroxyalkanoates in Arabidopsis peroxisomes, and their use in monitoring short-chain-length intermediates of beta-oxidation. | 2002 May |
|
Sensitive and real-time determination of H2O2 release from intact peroxisomes. | 2002 May 1 |
|
Genetic analysis--a diagnostic tool for primary hyperoxaluria type I. | 2002 Nov |
|
Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors. | 2002 Nov 1 |
|
Carbon exchange in hot alkaline degradation of glucose. | 2002 Nov 29 |
|
[Clinical study of the combination of small amount of nedaplatin (CDGP)/5-FU with radiation for the treatment of esophageal cancer]. | 2002 Oct |
|
A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients. | 2002 Sep |
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:36:49 UTC 2023
by
admin
on
Wed Jul 05 22:36:49 UTC 2023
|
Record UNII |
0WT12SX38S
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
2395-2
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
||
|
LOINC |
73883-1
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
||
|
LOINC |
25106-6
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
||
|
LOINC |
55864-3
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
||
|
LOINC |
13751-3
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
||
|
LOINC |
55865-0
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
||
|
LOINC |
54286-0
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
||
|
LOINC |
55863-5
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
||
|
LOINC |
20831-4
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
||
|
LOINC |
2396-0
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
||
|
LOINC |
73882-3
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
||
|
FDA ORPHAN DRUG |
872422
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
||
|
EPA PESTICIDE CODE |
101
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
||
|
LOINC |
78749-9
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
||
|
LOINC |
26682-5
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
||
|
LOINC |
42502-5
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
757
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
PRIMARY | |||
|
166
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
PRIMARY | |||
|
DB03085
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
PRIMARY | |||
|
SUB23402
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
PRIMARY | |||
|
C45678
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
CONCEPT | Industrial Aid | ||
|
4645
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
PRIMARY | |||
|
29805
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
PRIMARY | |||
|
DTXSID0025363
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
PRIMARY | |||
|
79-14-1
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
PRIMARY | |||
|
Glycolic Acid
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
PRIMARY | |||
|
100000088717
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
PRIMARY | |||
|
70603
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
ALTERNATIVE | |||
|
0WT12SX38S
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
PRIMARY | |||
|
17497
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
PRIMARY | |||
|
587318
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
PRIMARY | |||
|
201-180-5
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
PRIMARY | |||
|
C83737
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
PRIMARY | |||
|
5227
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
PRIMARY | |||
|
M5804
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
PRIMARY | Merck Index | ||
|
0WT12SX38S
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
PRIMARY | |||
|
GLYCOLIC ACID
Created by
admin on Wed Jul 05 22:36:49 UTC 2023 , Edited by admin on Wed Jul 05 22:36:49 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |